Teva Pharma
TEVA Large CapHealthcare · Drug Manufacturers - Specialty & Generic
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Teva Pharma en bref
Teva Pharma (TEVA) is currently trading at 30,35 € with a market capitalization of 35,4 Md €. The trailing P/E ratio stands at 58.35x, with a forward P/E of 11.39x. The 52-week range spans from 13,40 € to 32,38 €; the current price is 6.3% below the yearly high. Year-over-year revenue growth stands at -0.8%. The net profit margin stands at 4.08%.
💰 Dividende
Teva Pharma currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
10 analystes évaluent Teva Pharma (TEVA) au consensus : Achat Fort. L'objectif de cours moyen est de 35,72 €, soit un potentiel de +17.68% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 28,61 € à 43,35 €.
Teva Pharma : la thèse d'investissement en détail
Teva Pharma (TEVA) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in Israel. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Strong Buy with an average price target implying roughly 17.68% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Revenue is contracting at -0.8% year-over-year — until that trend reverses, valuation is exposed to further downgrades. With a net margin of just 4.08%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion.
Valorisation en contexte
With a PEG ratio of 0.96, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
Signal Smart Money
On the institutional side, Teva Pharma appears in the disclosed holdings of Druckenmiller. Smart-money managers track positioning, fundamentals and competitive dynamics with research budgets few retail investors can match — when several converge on the same name, it is rarely random. That doesn't mean blind copying makes sense, but it does raise the bar for the bear case.
À surveiller
- The forward P/E of 11.39x is meaningfully below the trailing 58.35x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 52.46% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Free cash flow positif
- –CA en contraction (-0.8% sur un an)
- –Faible rentabilité (marge 4.08%)
- –Multiple de valorisation élevé (P/E 58.35x)
- –Actuellement jugée surévaluée
- –Endettement élevé (D/E 217.79)
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Teva Pharma?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news